Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;25(1):102-112.
doi: 10.18553/jmcp.2019.25.1.102.

Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review

Emily Leonard  1 , Michael Wascovich  2 , Sonia Oskouei  3 , Paula Gurz  4 , Delesha Carpenter  1
Affiliations

Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review

Emily Leonard et al. J Manag Care Spec Pharm. 2019 Jan.

Abstract

Background: Newly developed biosimilar agents confer significant cost-saving advantages, yielding the potential to mitigate rising drug costs and expand patient access to care for important biologic therapies. Biosimilar market uptake greatly depends on health care provider willingness to promote, prescribe, and use biosimilars in clinical practice.

Objective: To perform a systematic review evaluating current U.S. and European health care provider knowledge, perceptions, and prescribing behaviors of biosimilar medicines to assess the need for clinician-directed biosimilar education.

Methods: An electronic literature search was conducted using journal databases, including PubMed, Embase, and Cochrane Library. Terms related to biosimilar agents, survey questionnaires, and education were used. Two independent reviewers evaluated 158 citations published from January 1, 2014, to March 5, 2018 that were the result of this search. Studies in English were included if they surveyed U.S. or European physician and/or pharmacist knowledge, attitudes, and/or prescribing preferences of biosimilar drugs. Overall trends in prescribing behavior and perceptions were abstracted.

Results: A total of 20 studies met inclusion criteria. Three studies originated from the United States and 17 were from Europe. Hospital specialists, gastroenterologists, and rheumatologists were the most frequently surveyed practitioners. The percentage of biosimilar prescribing varied widely between countries and within similar practice fields. If used, biosimilars were predominantly prescribed in biologic treatment-naive patients. An overall lack of biosimilar familiarity in U.S. and European health care settings accompanied concerns about biosimilar safety, efficacy, extrapolation, and interchangeability. Detailed descriptions of biosimilar education programs were lacking within the literature.

Conclusions: Findings from this review indicate that U.S. and European health care providers still approach biosimilar medicines with caution, citing limited biosimilar knowledge, low prescribing comfort, and safety and efficacy concerns as main deterrents for biosimilar use. To realize the full cost-saving potential of biosimilar medicines, clinician-directed biosimilar education will be imperative to address gaps in biosimilar knowledge, facilitate prescribing changes, and ultimately increase biosimilar use.

Disclosures: No outside funding supported this study. The authors have nothing to disclose.

PubMed Disclaimer

Conflict of interest statement

No outside funding supported this study. The authors have nothing to disclose.

Figures

FIGURE 1
FIGURE 1
Flow Diagram of Article Selection Process
See this image and copyright information in PMC

References

    1. Schumock GT, Li EC, Wiest MD, et al. . National trends in prescription drug expenditures and projections for 2017. Am J Health Syst Pharm. 2017;74(15):1158-73. - PubMed
    1. Mócsai A, Kovács L, Gergely P. What is the future of targeted therapy in rheumatology: biologics or small molecules? BMC Med. 2014;12(1):1-9. - PMC - PubMed
    1. U.S. Food and Drug Administration . Biosimilar development, review, and approval. 2017. Available at: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelope.... Accessed November 1, 2018.
    1. Generics and Biosimilars Initiative . Biosimilars approved in the U.S. February 9, 2018. Available at: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-the-US. Accessed November 1, 2018.
    1. Generics and Biosimilars Initiative . Biosimilars approved in Europe. February 2, 2018. Available at: http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Eu.... Accessed November 1, 2018.

Publication types

MeSH terms

Substances

LinkOut - more resources